ARCHIVES

Merck Serono Cancels Tecemotide Program In NSCLC, Including Two Phase III Trials

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

Two Regorafenib Trials Demonstrate Efficacy, Improve Overall and Progression-Free Survival

December 28, 2012

Joint NCI/FDA Program approved; ‘May Solve Our Differences’

December 15, 1989

Patenting the Gene: Cancer Advocates and Industry Diverge on Myriad Ruling

June 14, 2013

UT System Launches Probe of Submission Of Controversial MD Anderson Grant

June 8, 2012

ASCO, AACR Hold Last Joint annual Meeting, Vow to Encourage Basic-Clinical Interaction

May 28, 1993

Congress Cuts $210 Million From NIH Budget For The Remainder of 2011

April 15, 2011